Table 1 Baseline characteristics of 249 patients enrolled in the DRV/COBI cohort
Dual therapy | Triple therapy | P | |||
|---|---|---|---|---|---|
N | % | N | % | ||
Enrolled patients | 72 | 28.9 | 177 | 71.1 | |
Female | 28 | 38.9 | 39 | 22.0 | 0.007 |
Risk factor for HIV acquisition | |||||
Sexual | 30 | 41.7 | 103 | 58.2 | |
Intravenous drug use | 29 | 40.3 | 46 | 26.0 | |
Transfusion/vertical/unknown | 13 | 5.6 | 28 | 1.1 | 0.04 |
Ethnicity | |||||
Caucasian | 70 | 97.2 | 165 | 93.2 | |
Other | 2 | 2.8 | 12 | 6.8 | 0.21 |
Naive | 1 | 1.4 | 8 | 4.5 | 0.45 |
CDC stage | |||||
A | 15 | 20.8 | 47 | 26.6 | |
B | 40 | 55.6 | 68 | 38.4 | |
C | 17 | 23.6 | 62 | 35.0 | 0.59* |
HIVRNA > 50 copies/mL at T0** | 11 | 15.5 | 12 | 7.1 | 0.04 |
Previous regimen including** | |||||
PI | 61 | 85.9 | 161 | 95.3 | 0.01 |
NNRTI | 15 | 21.1 | 4 | 2.4 | < 0.0001 |
Hypercholesterolemia | 44 | 61.1 | 77 | 43.5 | 0.03 |
Hypertriglyceridemia | 11 | 15.3 | 30 | 16.9 | 0.67 |
Mean or median | SD or IQR | Mean or median | SD or IQR | ||
|---|---|---|---|---|---|
Mean age, SD (years) | 50.2 | 10.8 | 48.2 | 10.1 | 0.17 |
Mean CD4, SD (cells/mm3) | 625 | 381 | 581 | 343 | 0.37 |
Median time on PI, IQR (years) | 8.8 | 5.9–11.5 | 5.8 | 2.5–10.0 | 0.001 |
Median time on NNRTI, IQR (years) | 2.4 | 0.9–4.8 | 1.6 | 0.1–5.3 | 0.12 |
Median time on ART, IQR (years) | 18.1 | 7.8–21.0 | 9.0 | 3.2–17.9 | < 0.0001 |
Mean eGFR, SD (mL/min) | 94.2 | 20.3 | 96.3 | 23.6 | 0.50 |